Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple MyelomaJennifer N Brudno, Irina Maric, Steven D Hartman, et al.Blood|October 14, 2010
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaYair Herishanu, Patricia Pérez-Galán, Delong Liu, et al.Leukemia & Lymphoma|October 1, 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasoneElisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.Blood|September 15, 2021
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A Lichtenstein, Fiorella Schischlik, Lipei Shao, et al.JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.Cytotherapy|November 5, 2025
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, et al.JAMA Oncology|July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Mark Roschewski, Adriana Zingone, et al.Pageof 3